GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LogicBio Therapeutics Inc (NAS:LOGC) » Definitions » Beneish M-Score

LogicBio Therapeutics (LogicBio Therapeutics) Beneish M-Score : 0.00 (As of May. 06, 2024)


View and export this data going back to 2018. Start your Free Trial

What is LogicBio Therapeutics Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for LogicBio Therapeutics's Beneish M-Score or its related term are showing as below:

During the past 6 years, the highest Beneish M-Score of LogicBio Therapeutics was 0.00. The lowest was 0.00. And the median was 0.00.


LogicBio Therapeutics Beneish M-Score Historical Data

The historical data trend for LogicBio Therapeutics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LogicBio Therapeutics Beneish M-Score Chart

LogicBio Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Beneish M-Score
Get a 7-Day Free Trial - - - - -4.58

LogicBio Therapeutics Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.40 -3.39 -4.58 -3.32 -1.09

Competitive Comparison of LogicBio Therapeutics's Beneish M-Score

For the Biotechnology subindustry, LogicBio Therapeutics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LogicBio Therapeutics's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LogicBio Therapeutics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where LogicBio Therapeutics's Beneish M-Score falls into.



LogicBio Therapeutics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of LogicBio Therapeutics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0+0.528 * 1+0.404 * 1.6563+0.892 * 3.721+0.115 * 0.634
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.2973+4.679 * -0.054172-0.327 * 1.6222
=-1.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun22) TTM:Last Year (Jun21) TTM:
Total Receivables was $0.00 Mil.
Revenue was 3.199 + 2.816 + 2.027 + 2.12 = $10.16 Mil.
Gross Profit was 3.199 + 2.816 + 2.027 + 2.12 = $10.16 Mil.
Total Current Assets was $40.79 Mil.
Total Assets was $47.02 Mil.
Property, Plant and Equipment(Net PPE) was $5.61 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.68 Mil.
Selling, General, & Admin. Expense(SGA) was $15.29 Mil.
Total Current Liabilities was $18.09 Mil.
Long-Term Debt & Capital Lease Obligation was $6.49 Mil.
Net Income was -5.044 + -6.662 + -9.063 + -10.185 = $-30.95 Mil.
Non Operating Income was 0 + 0 + -0.015 + -0.003 = $-0.02 Mil.
Cash Flow from Operations was -3.019 + -9.901 + -5.161 + -10.308 = $-28.39 Mil.
Total Receivables was $0.08 Mil.
Revenue was 0.802 + 0.461 + 0.542 + 0.926 = $2.73 Mil.
Gross Profit was 0.802 + 0.461 + 0.542 + 0.926 = $2.73 Mil.
Total Current Assets was $70.02 Mil.
Total Assets was $77.88 Mil.
Property, Plant and Equipment(Net PPE) was $7.23 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.54 Mil.
Selling, General, & Admin. Expense(SGA) was $13.82 Mil.
Total Current Liabilities was $14.16 Mil.
Long-Term Debt & Capital Lease Obligation was $10.93 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0 / 10.162) / (0.077 / 2.731)
=0 / 0.028195
=0

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(2.731 / 2.731) / (10.162 / 10.162)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (40.786 + 5.609) / 47.017) / (1 - (70.024 + 7.229) / 77.875)
=0.013229 / 0.007987
=1.6563

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=10.162 / 2.731
=3.721

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.535 / (0.535 + 7.229)) / (0.684 / (0.684 + 5.609))
=0.068908 / 0.108692
=0.634

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(15.285 / 10.162) / (13.815 / 2.731)
=1.504133 / 5.058587
=0.2973

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((6.487 + 18.085) / 47.017) / ((10.929 + 14.159) / 77.875)
=0.522619 / 0.322157
=1.6222

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-30.954 - -0.018 - -28.389) / 47.017
=-0.054172

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

LogicBio Therapeutics has a M-score of -1.09 signals that the company is likely to be a manipulator.


LogicBio Therapeutics Beneish M-Score Related Terms

Thank you for viewing the detailed overview of LogicBio Therapeutics's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


LogicBio Therapeutics (LogicBio Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
65 Hayden Avenue, 2nd Floor, Lexington, MA, USA, 02421
LogicBio Therapeutics Inc is a genome editing company focused on developing medicines to durably treat rare diseases in patients with significant unmet medical need using GeneRide, its proprietary technology platform. Its product candidates include LB-001, LB-101, LB-201 and LB 301.
Executives
Mark J Enyedy director C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
Mariana Nacht officer: Chief Scientific Officer 65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Daniel Gruskin officer: Chief Medical Officer 65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Susan Kahn director 65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Joshua Blacher officer: Interim CFO 65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Andrea Paul officer: General Counsel and Secretary 65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Frederic Chereau director, officer: See Remarks C/O ATYR PHARMA, INC., 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Kyle Chiang officer: Chief Operating Officer 65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Cecilia Jones officer: Chief Financial Officer C/O LOGICBIO THERAPEUTICS, INC., 65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Jonathan Quick officer: Senior Director-Finance C/O LOGICBIO THERAPEUTICS, INC., 65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Jeff Goater director C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139
Daphne Karydas director 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
Erez Chimovits director P.O. BOX 4023, HERZLIYA PITUACH L3 4614001
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Genesis Gp Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022

LogicBio Therapeutics (LogicBio Therapeutics) Headlines

From GuruFocus